New study shows that Kemin's algae-based beta-glucan ingredient reduced symptoms of upper respiratory tract infection as well as the number of sick days of subjects.
Photo © iStockphoto.com/Matt_Brown
Kemin Industries (Des Moines, IA) has announced the results of a clinical trial demonstrating the immune health benefits of its BetaVia Complete ingredient, which is a proprietary strain of Euglena gracilis, a nutrient-rich algae with greater than 50% 1,3 beta glucan content. The study, completed in the fall of 2018 and awaiting publication, is a randomized, double-blind, placebo-controlled clinical trial conducted over the course of 90 days. During the trial, researchers utilized the Wisconsin Upper Respiratory Symptoms Survery to collect self-reporting information from active adults that has upper respiratory tract infections (URTIs).
Results showed that, compared to placebo, subjects taking BetaVia experienced 70% fewer URTI symptoms, four less sick days, and 10 fewer URTI symptom days over the 90-day period. “With increasing consumer demand for products that are both plant-based and offer immune support, we are excited by the study results, which show BetaVia Complete may give people around the world an opportunity to live a healthier life,” commented Josh Swalla, product manager of BetaVia ingredients, in a press release.
Polyphenols: The next generation of prebiotics is ready for liftoff
April 21st 2025Explore the prebiotic health benefits of polyphenols and the positive impact they may have on digestive and immune health. Polyphenols, such as those found in European black elderberry, may be an ideal solution for manufacturers trying to break into the digestive health space.